Published in final edited form as:

Int J Clin Rheumatol. 2012 April 1; 7(2): 217–227. doi:10.2217/IJR.12.4.

Fatigue in systemic lupus erythematosus

Grace E Ahn* and Rosalind Ramsey-Goldman

Division of Rheumatology, Northwestern University, 240 E. Huron St. McGaw M300, Chicago, IL 6061, USA

Abstract

Systemic lupus erythematosus is a chronic inflammatory autoimmune disease often characterized by fatigue, with significant effects on physical functioning and wellbeing. The definition, prevalence and factors associated with fatigue, including physical activity, obesity, sleep, depression, anxiety, mood, cognitive dysfunction, vitamin D deficiency/insufficiency, pain, effects of medications and comorbidities, as well as potential therapeutic options of fatigue in the systemic lupus erythematosus population are reviewed. Due to variability in the reliability and validity of various fatigue measures used in clinical studies, clinical trial data have been challenging to interpret. Further investigation into the relationships between these risk factors and fatigue, and improved measures of fatigue, may lead to an improvement in the management of this chronic inflammatory disease.

Keywords

anxiety; depression; fatigue; physical activity; sleep; systemic; lupus erythematosus; vitamin D

The prevalence of systemic lupus erythematosus (SLE) in the USA is estimated to be 15–50 per 100,000 population [1]. There is variability in the reliability and validity of various fatigue measures used in clinical studies. There are also inconsistent findings regarding the usefulness of biomarkers and imaging studies as measures of fatigue in SLE that we also discuss. Finally, we present the knowledge gaps where further research is needed to more precisely measure fatigue to facilitate efficacy assessments of the treatments for fatigue.

Overview of SLE

SLE is a chronic inflammatory autoimmune disease with an unknown cause [1]. The disease can affect the nervous system, skin, joints, serous membranes, kidneys, lungs, as well as other organs. Although SLE can occur in males as well as neonates and children, it is more common in females in their 20s and 30s, especially in non-Caucasian populations including the African-American, Hispanic and Asian populations. The etiology of this disease is still unknown with genetic, environmental, immunologic and hormonal factors contributing to disease susceptibility and severity [2–9].

The American College of Rheumatology's revised classification criteria, published in 1997, for inclusion in SLE research studies, is used to classify eligible patients with SLE if they

© 2012 Future Medicine Ltd

*Author for correspondence: Tel.: +1 312 503 3101, Fax: +1 312 503 0994, g-ahn@md.northwestern.edu.

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

have four out of 11 clinical and laboratory criteria. There is an ongoing effort to update the 1997 criteria to incorporate new knowledge regarding clinical and laboratory manifestations of SLE [10].

Patients with SLE have heterogeneous clinical features including complaints of fever, malaise, weight loss, fatigue and photosensitivity. Documentation on physical examination often shows nasal or oral ulcers, alopecia, skin lesions, including malar or discoid skin lesions, joint pain and swelling, pericarditis or pleuritis, or lymphadenopathy. The patients may also have laboratory abnormalities not attributed to other causes such as leukopenia, lymphopenia, thrombocytopenia, elevated creatinine, proteinuria or positive autoantibodies. Severely affected patients may have neurologic sequela such as seizures or psychosis, or renal failure requiring renal replacement therapy with hemodialysis or peritoneal dialysis or renal transplant.

SLE & fatigue

Although there is no clear consensus on a definition for fatigue, Piper has defined fatigue as “an uncommon, abnormal or extreme whole bodily tiredness disproportionate or unrelated to activity or exertion” [11]. Studies have shown that 53–80% of SLE patients have identified fatigue as one of their primary symptoms [11]. When fatigue severity was rated, the scores were similar to previous observations in patients with other chronic illnesses, such as Lyme disease and multiple sclerosis, and higher than the general population [12,13]. One of the major causes of morbidity in SLE patients is chronic, debilitating fatigue [14], decreasing quality of life [15–17], increasing risk of work disability [18] with associated cumbersome healthcare costs [19].

Etiology of fatigue in SLE

The etiology of fatigue in the SLE population is multifactorial and is associated with physical activity, obesity, sleep quality, depression, anxiety, mood, cognitive dysfunction, vitamin D deficiency/insufficiency, comorbidities such as fibromyalgia, or related to the SLE disease itself or the treatments used to manage SLE.

Physical activity & fatigue in SLE

Previous studies of patients with SLE have shown the impact of aerobic or muscle strengthening or supervised exercise strategies on improved health outcomes including fatigue [20,21], improved exercise tolerance [21–23] and quality of life [22,24]. When aerobic capacity is measured in the physiology laboratory, even patients with mild SLE struggle with performing daily activities and their performance is comparable to levels in individuals with severe cardiopulmonary and metabolic disease [25–27]. SLE patients were found to be less fit with reduced levels of aerobic fitness and reduced exercise capacity including reduced muscle strength, reduced resting lung function, depressed mood, poor sleep quality and functional incapacity, and this physical disability correlated with increased levels of fatigue by a linear regression model [24]. In one study of women with SLE that measured aerobic capacity (maximal oxygen uptake/ VO_2 max) with a bicycle ergometer exercise test during low-to-moderate activity, VO_2 max was significantly lower in SLE females than levels predicted for sedentary women [28]. Another study looking at SLE women and aerobic capacity supported the previous study’s findings that aerobic capacity measured by peak oxygen consumption during the treadmill tests was decreased in SLE women compared to controls, was lower than expected for physiologic deconditioning and that this aerobic insufficiency was highly correlated with the perception of severe, activity-limiting fatigue in this population [26].

The list of potential ramifications of low physical activity on health outcomes in SLE was recently extended to include an increased risk of cardiovascular disease as measured by increased proinflammatory biomarkers (e.g., proinflammatory high density lipoprotein [HDL]), the presence of carotid plaques [29–31] and other adverse health outcomes [32].

Mancuso and colleagues compared physical activity levels with clinical and psychosocial variables including fatigue, depression, social support and stress in 50 patients with SLE. Patients who described more stress and fatigue also reported less physical activity [32]. Only 14 out of 50 (28%) patients met the US government public health goal for the general population of at least 150 min/week of moderate-to-vigorous intensity physical activity. Although 92% of SLE patients believed that physical activity was beneficial for SLE and that they could be more physically active, over 78% believed that SLE impeded their ability to exercise. Patients expressed fears about getting injured during exercise, but they thought physical activity would be beneficial if it were managed appropriately. Fatigue, exposure to sunlight, joint pain, hematologic and bony abnormalities predisposing patients to bleeding and fracture were among the patient-reported physical activity barriers cited to be specific to SLE [32].

Obesity & fatigue in SLE

The prevalence of obesity in SLE is between 28 and 50% [33–35]. Few studies have documented associations between diet and nutrient density with SLE and/or fatigue, although adverse associations between obesity and fibromyalgia, functional capacity based on the difficulty performing activities of daily living and inflammatory markers have been noted in SLE [36–38]. Data from LUMINA, a multiethnic SLE cohort study, showed that 28% of the patients were obese, with a BMI of 30 kg/m² and above, and that this was associated with worse depression and fatigue [36]. Another study showed a prevalence of obesity of 39% and demonstrated a positive association between obesity and higher levels of fatigue in the SLE cohort [37]. Obesity and SLE are both inflammatory diseases with evidence of increased TNF- α levels in SLE and evidence of increased C-reactive protein and IL-6 levels [39–42]. Higher concentrations of both C-reactive protein and IL-6 increase concerns that these patients may be at higher risk of developing vascular disease. Identifying obesity as a cause of fatigue and poor quality of life in SLE is important, because this risk factor can potentially be modified.

Sleep & fatigue in SLE

Sleep disturbances in patients with SLE are common and prevalence can be as high as 91.5% [43–46]. In chronic inflammatory diseases including SLE, sleep–wake disturbances are thought to worsen the disease symptoms including fatigue and lower the patient's quality of life. The pathogenesis behind sleep disturbances are thought to be the result of pain, stress or depression from the disease itself; either owing to the medications used for treatment, or owing to immune changes from the disease [47]. Patients with SLE report poor sleep quality including frequent awakenings and restlessness. Self-reported questionnaires were used to assess levels of fatigue in 48 SLE female patients in comparison to 27 controls. SLE patients had greater fatigue compared to controls, with reports of longer sleep latency and total sleep time without a higher prevalence of depression [48]. Iaboni *et al.* conducted a study using a polysomnogram showing patterns of low sleep efficiency (defined as total sleep time during time in bed attempting to sleep), deficits in slow-wave sleep, high frequency of arousals during sleep and high levels of α -EEG sleep activity in SLE patients compared to healthy controls, which was comparable to the pattern of unrestorative sleep found in patients with fibromyalgia. However, there was no significant association between sleep and clinical features of SLE disease or disease activity. Mild-to-moderate depression was found among the study population, but they found that sleepiness in SLE patients was not associated with

depression. SLE patients with severe depression complained mostly of tiredness but were not always objectively sleepy. The authors concluded that primary sleep disorders are common among SLE patients and are related to their fatigue, but distinct from depression contributing to fatigue [49].

Other studies supported the finding of increased unrestorative sleep in SLE patients by showing high frequency of primary sleep disorders including sleep apnea and abnormal limb movements during sleep in SLE patients, as well as increased daytime sleepiness due to sleep fragmentation and more arousals [50,51]. One study assessed 100 women with SLE and their sleep quality by utilizing the Pittsburgh Sleep Quality Index [52], a questionnaire that assesses sleep quality and disturbances over a 1-month period. Completed questionnaires reflected moderate-to-severe sleep impairments in 56% of the SLE population. Cumulative damage, disease activity, functional disability, pain severity, use of prednisone, depressed mood and lower levels of exercise participation were all positively correlated with poorer sleep quality [46].

Depression, anxiety, mood, cognitive dysfunction & fatigue in SLE

The prevalence of depression and anxiety in SLE is as high as 28 and 24%, respectively [53]. Depression has been consistently associated with fatigue in SLE patients [13,17,24,45,48,54–56]. In a study by Krupp *et al.*, the degree of depression among patients with SLE was measured by the Center for Epidemiologic Studies Depression scale [56], a 20 item validated inventory (higher scores suggest a higher risk of depression) [57]. The scores of SLE patients were higher than the normal population but milder when compared to psychiatric patients, and similar to those with other chronic medical conditions. However, the correlation between fatigue scoring and depression was higher in the SLE population than other medical conditions such as Lyme disease or multiple sclerosis [12,36,56].

Anxiety and mood disorders have been implicated as one of the contributing factors of fatigue in SLE [48,56]. Tench *et al.* used questionnaires to measure self-reported fatigue, disease activity, sleep quality, quality of life, anxiety and depression in 120 SLE patients [45]. Anxiety and depression were measured using the Hospital Anxiety and Depression scale (HAD) [58], which is used to assess mood in patients with physical disease. A HAD score of eight or above suggests a possible mood disorder and ten or above suggests a pathological mood disorder. Approximately one third of these patients had HAD scores suggestive of a pathological mood disorder, and in contrast approximately 13% were taking antidepressant medications. The authors concluded that since a moderate correlation was seen between HAD depression scores and fatigue, depression and anxiety may contribute to SLE fatigue [45].

Little is known about the pathology behind cognitive dysfunction associated with fatigue in the SLE population, although cognitive impairment has been one of the main complaints in patients with SLE compared to controls [59]. Prevalence of cognitive dysfunction in SLE patients ranges from 27 to 61%, with deficits shown in learning or memory, reasoning, fluency and attention, as well as processing speed deficits [60–62]. Kozora *et al.* examined neuropsychological and neurologic functioning in 67 SLE patients without histories of overt neuropsychiatric disorders compared to 29 healthy controls. Results showed that SLE patients had significantly higher rates of impairment on logical reasoning and verbal memory, and trends towards greater impairment in visual attention and working memory [63]. These patients also had higher depressive symptoms and perceived cognitive difficulties compared with controls on the Beck Depression Inventory [64] and the Cognitive Failures Questionnaire [65], respectively.

Vitamin D & fatigue in SLE

Vitamin D plays a crucial role in bone metabolism and bone health [66,67], with recent studies suggesting vitamin D deficiency playing an important role in cardiovascular disease, cancer and autoimmune diseases. Vitamin D deficiency has been related to higher risk of cardiovascular disease, increased risk in all-cause mortality in the general population, as well as increased risk of autoimmune diseases including SLE [66,68,69]. Although the role of vitamin D in the pathogenesis and clinical course of SLE are largely unknown, suboptimal levels of vitamin D have been reported in the SLE population [70–72]. A relationship between fatigue and vitamin D insufficiency, defined as serum levels of 25-hydroxyvitamin D (25[OH]D) below 30 ng/ml, and deficiency, defined as serum levels of 25(OH)D below 10 ng/ml, were found in a study by Ruiz-Irastorza *et al.* Among 92 patients with SLE, 75% presented with vitamin D insufficiency and 15% with vitamin D deficiency. The high prevalence of vitamin D insufficiency and deficiency in the SLE population is multifactorial and is exacerbated by specific issues related to SLE such as the recommendation to avoid sun exposure because of the risk of increased disease activity from photosensitivity. SLE patients with vitamin D deficiency had a higher degree of fatigue on the 0–10 visual analog scale (VAS) with a mean score of 5.32 compared to 4.03 in patients with 25(OH)D levels above 10 ng/ml ($p = 0.08$). The authors concluded that critically low 25(OH)D levels below 10 ng/ml was an independent predictor of higher values of VAS used to measure fatigue, and suggested checking vitamin D levels in SLE patients experiencing tiredness [73]. In an observational study by the same author where oral vitamin D3 was supplemented for low 25(OH)D levels in SLE patients, fatigue quantified by VAS improved in the cohort members who used the oral supplements. They also found an inverse association between 25(OH)D levels and the VAS score [74].

Pain & fatigue in SLE

Pain related to arthralgias and arthritis can occur in up to 95% of SLE patients during the course of their disease [75]. Zonana-Nacach *et al.* found that pain among other psychosocial cofactors does contribute to higher levels of fatigue in these patients [76]. In this study, patients subjectively estimated their pain attributable to SLE with 0–10 VAS, and fatigue was measured with the Fatigue Severity Scale (FSS) [77]. During their analysis, a significant positive association was found between levels of fatigue and self-reported pain attributed to SLE among other variables [76]. Jump *et al.* studied correlations between pain, psychological distress and their association with fatigue in SLE patients. One hundred and twenty-seven participants completed questionnaires for fatigue, disease activity, pain and depression. As predicted, fatigue was the most highly rated symptom compared to other complaints, with higher scores seen on VAS for pain. When they conducted a correlational analysis, fatigue was moderately associated with pain intensity ($r = 0.43$; $p < 0.001$) and depression ($r = 0.48$; $p < 0.001$) [78].

Medication & fatigue in SLE

Reports suggest that medications used to treat SLE may themselves be associated with fatigue. One study showed that fatigue scores did not differ significantly between SLE patients taking corticosteroids and those who were not taking corticosteroids, but patients taking NSAIDs reported significantly higher fatigue scores compared to those who were not. Pain scores were reported to be higher among those patients taking NSAIDs, but when corrected for pain as a contributing factor for the fatigue scoring, the difference was no longer apparent. Also the use of psychotropic medications such as antidepressants or anxiolytics did not make a significant difference on the reporting of subjective fatigue between those taking and those not taking these medications [78].

Comorbidities & fatigue in SLE

Fibromyalgia can be seen from as low as 10% to as high as 70% in study populations coexisting with SLE [49]. Fibromyalgia coexisting with SLE has been thought to contribute to fatigue in SLE patients [78]. One study showed a prevalence of fibromyalgia in only 10% of 216 SLE patients complaining of fatigue [50], but another study showed higher prevalence of fatigue in SLE patients with a pain syndrome although these patients did not fit the American College of Rheumatology's criteria for fibromyalgia [79]. Since fibromyalgia may coexist with SLE-diagnosed patients, comorbidities other than SLE itself causing fatigue in this patient population should be considered. Thyroid disease and anemia have also been implicated as affecting fatigue in SLE patients [14].

Disease activity & fatigue in SLE

One would suspect that having SLE, a chronic disease, itself would contribute to fatigue, but findings have been more conflicting, with some showing significant positive association [13,80,81], and others with weak or no association [45,56,76,78,79,82–85]. Wang *et al.* studied the relationship between fatigue and disease activity in the SLE population using the Systemic Lupus Erythematosus Disease Activity Index and fatigue using the FSS. No significant correlation between FSS and Systemic Lupus Erythematosus Disease Activity Index were found, and they concluded that fatigue in SLE patients does not correlate with disease activity [84]. Another study demonstrated that fatigue symptoms do not correlate well with any of the laboratory measures, but physician's rating of disease activity correlated well with patient's fatigue [56]. Tayer *et al.* investigated the contributions of disease status, feeling of helplessness and depression to fatigue in SLE patients. Eighty one SLE patients underwent clinical evaluation with the Systemic Lupus Activity Measure and completed self-reported questionnaires on psychosocial data, depression, feelings of helplessness and fatigue. The authors concluded that SLE disease status predicted fatigue at two different time points in the longitudinal analysis, independent of depression and helplessness, by using hierarchical multiple regression analyses [80].

Measurements of fatigue

Survey instruments

Although fatigue can only be measured subjectively, the impact of fatigue on quality of life is still important. There have been inconsistent definitions for fatigue used in clinical studies utilizing different instruments to measure fatigue. At least 30 different scales are available to test fatigue in general. Owing to the inconsistencies, an *Ad Hoc* Committee on SLE response criteria systematically reviewed the literature on validated instruments on fatigue used in SLE. Fifteen different fatigue instruments were reviewed focusing on validity, reliability and responsiveness, as well as correlations between fatigue and cofactors, such as disease activity, depression, pain and sleep. The instruments surveyed included the FSS, Chalder Fatigue Scale [86], Robert B. Brigham Multipurpose Arthritis Center-Fatigue Scale [23], Piper Fatigue Scale [87], Short Form of the Medical Outcome Study questionnaire plus one item for fatigue [88], Fatigue Self-Efficacy Scale (FSES) [89], Short Form-36 vitality subscale [90], Multidimensional Assessment of Fatigue [91], Multidimensional Fatigue Inventory 20 items [92], fatigue rating [81], VAS [93], Fatigue Assessment Instrument FAI [94], VAS-fatigue [95], Sjogren's-Based Psychometric Instrument [96] and single question for fatigue [50]. Among the 34 SLE studies that used these 15 instruments, the FSS was most commonly used and thought to have a homogeneous pattern in measuring outcomes when applied to studies, making it a clinically important scale to be used in future studies. The panel concluded that this instrument was developed specifically for patients with SLE and had valid psychometric properties including internal consistency, responsiveness and construct validity. They proposed that an improvement or response of 15% decrease in the

FSS was considered clinically important but called for future studies to test this recommendation [77].

Biomarkers

Possible correlations between serum biomarkers for inflammation in SLE and fatigue were evaluated in a cross-sectional study. Some changes in cytokine levels have been observed in SLE, with shifts towards Type 2 cytokines such as IL-2, IL-6, IL-10, TNF- α and INF- α [97–99]. In chronic fatigue syndrome patients, increased levels of TGF- β , TNF- α , IL-2 and IL-6 with other cytokines are seen [100–102]. These studies concluded that these cytokines do play a role in fatigue, with profound fatigue after infusion of these cytokines and immediate improvement in fatigue following anti-IL-6-receptor antibody therapy [103–106]. Omdal *et al.* studied SLE patients to determine whether fatigue was associated with levels of serum cytokines including TNF- α , IL-2, IL-6, IL-10, TGF- β , IFN- α , antiphospholipid antibodies including anticardiolipin antibody and β 2-glycoprotein I antibody, as well as changes seen in cerebral MRI. Among 57 patients, 45 (79%) reported fatigue on FSS and nine (17%) had cerebral infarcts on MRI, although no differences in FSS scores were observed between patients with or without infarcts on MRI. No particular associations were seen between FSS and anticardiolipin antibodies, β 2-glycoprotein I antibodies, TNF- α , IL-2, IL-6, IL-10, TGF- β and IFN- α , and the authors concluded that SLE markers of disease or inflammation, evaluated by serum cytokine levels and brain imaging, did not influence fatigue [83]. In the same study, the authors found that low levels of C4 were the only biomarker that correlated with fatigue.

Imaging

There have been inconsistent findings correlating the association of levels of fatigue to changes of brain imaging. The study by Omdal *et al.* did not find a significant association between infarcts seen on MRI to fatigue in SLE patients [83]. In another study by Harboe *et al.*, utilizing a semi-quantitative radiologic scale on a T2-weighted MRI study, noted that cerebral white matter hyperintensities (WMH), previously associated with cognitive impairment in multiple sclerosis, were also present in SLE patients [107]. The WMH changes are known to represent biochemical changes in brain tissue frequently seen in patients with SLE [80]. Among 62 SLE patients, fatigue scores measured by FSS and VAS were higher among SLE population (FSS 4.3 with SD 1.7 and VAS 48.9 with SD 30.1) compared to healthy subjects (FSS 2.3 with SD 1.0 and VAS 19.7 with SD 19.7). Eleven (18%) SLE patients had cerebral infarcts compared to two (3%) healthy subjects, and total WMH scores were higher in SLE patients compared to healthy subjects. Only fatigue measured by VAS, not FSS, correlated with total WMH score. The authors concluded that fatigue is associated with a higher cerebral WMH load in SLE patients, supporting evidence for the biological explanation for fatigue in patients with chronic autoimmune diseases [107]. Another study utilized single-photon emission computed tomography imaging to investigate whether disturbances of cerebral blood flow (CBF) can be seen in SLE patients with fatigue. Single-photon emission computed tomography resulted in focal CBF disturbance in 17 out of 57 (30%) patients and generalized CBF reductions in 32 out of 57 (57%) patients, although no significant association between CBF and degree of fatigue was seen. They concluded that there was no association between fatigue in SLE patients and disturbances of brain blood perfusion pattern [108].

Treatment of fatigue

Fatigue is a frequent and pervasive problem with multiple adverse consequences for patients with SLE, but to date there have only been a few clinical trials that have addressed the pharmacologic and nonpharmacologic management of fatigue in SLE populations.

Psychoeducational intervention has been used in trials compared to placebo, with reported improvement in social support between patients and their partners, better self-efficacy and lower fatigue after 1 year of therapy, calling for a role of behavioral therapy in the management of fatigue in SLE [109,110].

A pilot study to investigate the feasibility and safety of acupuncture for SLE explored the benefits of acupuncture in reducing pain and fatigue. Twenty four patients were randomized to receive acupuncture with electrical stimulation, minimal needling, which involves shallow insertion of needles into nonacupuncture body points, or usual care during ten sessions. No serious side effects occurred, although some minor transient side effects were reported, mainly needle insertion pain, dizziness or lightheadedness, or local bruising. A total of 40% of patients receiving active intervention with acupuncture or minimal needling reported more than a 30% improvement in pain scores measured by the Arthritis Impact Measurement Scale revised Pain Scale or the 36-item Short-Form Health Survey bodily pain scale [111–113]. Only 13% in the minimal needling group, but 25% in the acupuncture group showed improvement in fatigue, measured with FSS or 36-item Short-Form Health Survey vitality score, suggesting that a brief course of acupuncture may be a useful nonpharmacologic alternative for managing pain and fatigue for SLE patients [114].

A recent pilot study evaluated the effectiveness of home-based exercise programs using the Wii Fit® system in SLE patients. Fifteen patients who had moderate-to-severe fatigue measured by FSS participated in Wii Fit®, a fitness gaming module, 3 days a week for 30 min each time. Even though the mean adherence was 64% across the 10-week period, patients' perceived fatigue severity significantly improved by average of 18.4%, with added benefits of reduced body weight and waist circumference. Other improvements were seen including reduced anxiety level and pain, and the authors concluded that this method was safe and feasible and may be a viable option to encourage physical activity and reduce fatigue, body weight, waist circumference, anxiety and overall intensity of pain [115].

Hartkamp *et al.* investigated the role of dehydroepiandrosterone (DHEA) in improving fatigue and reduced wellbeing in patients with SLE in a randomized placebo-controlled trial of 60 patients [116]. Patients with SLE have frequently been found to have low levels of DHEA, which is a major steroidal product in the adrenal gland. Previous research studies observed a relationship between physiologic decline in serum DHEA and DHEA sulfate levels during aging with atherosclerosis, global changes in metabolism, decline in cerebral function and immunocompetence, potentially linking the DHEA to rheumatic diseases [117]. DHEA has shown some beneficial effects when administered in older patients and in patients with other disease states including cardiovascular disease [117]. This study was conducted in patients with quiescent SLE to avoid other confounding factors, with daily oral administration of 200 mg DHEA. Fatigue was measured using the Multidimensional Fatigue Inventory [92], with both placebo and DHEA groups improving on fatigue scores with no proven benefit of DHEA over placebo in improving fatigue [116].

A recent randomized, double-blind, placebo-controlled clinical trial of a newly approved B-lymphocyte stimulator, belimumab, has assessed fatigue as a secondary end point using the Functional Assessment of Chronic Illness Therapy Fatigue scale [118], and 52-week and 76-week studies showed a significant improvement in fatigue compared to placebo [119,120].

Future perspective

Fatigue is a primary complaint of patients with SLE. One critical research need is to improve the measurement of fatigue for use in clinical trials. One potential tool, Patient-Reported Outcomes Measurement Information System, uses rigorous instrument-development standards and item response theories to create questionnaires that can be used

across different clinical trials and varied disease conditions [95]. Improved unified fatigue measurements will facilitate further studies of fatigue and help guide therapy.

There is a constant interplay between different cofactors that may contribute to fatigue experienced by SLE populations, including poor sleep, depression, anxiety, mood disorders, physical inactivity, obesity, vitamin D insufficiency/deficiency, the disease itself, or other confounding comorbidities. Nonpharmacologic and pharmacologic interventions have been minimally to moderately effective in ameliorating fatigue and further investigations in these areas are needed.

Acknowledgments

R Ramsey-Goldman is supported by NIH/NIAMS grant R21AR059989. GE Ahn is a Driskill Foundation scholar at Northwestern University.

References

Papers of special note have been highlighted as:

■ of interest

■ ■ of considerable interest

1. Hahn, BH. Systemic Lupus Erythematosus (15th Edition). NY, USA: McGraw-Hill; 2001. p. 1922-1928.
2. Elkon K. Autoantibodies in systemic lupus erythematosus. *Curr. Opin. Rheumatol.* 1995; 7(5):384–388. [PubMed: 8519610]
3. Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. *Ann. NY Acad. Sci.* 2005; 1051:433–441. [PubMed: 16126985]
4. Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. *Springer Semin. Immunopathol.* 2006; 28(2):119–130. [PubMed: 17021721]
5. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. *Arthritis Rheum.* 1996; 39(12):2035–2045. [PubMed: 8961909]
6. Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. *Arthritis Rheum.* 2005; 52(12):3701–3712. [PubMed: 16320320]
7. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. *Arthritis Rheum.* 2003; 48(8):2100–2110. [PubMed: 12905462]
8. Schur PH. Genetics of systemic lupus erythematosus. *Lupus.* 1995; 4(6):425–437. [PubMed: 8749564]
9. Wong M, Tsao BP. Current topics in human SLE genetics. *Springer Semin. Immunopathol.* 2006; 28(2):97–107. [PubMed: 16941108]
10. Petri M, Orbai A, Alarcon G, Gordon C. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 2011 (In press). ■ ■ New proposal for systemic lupus erythematosus (SLE) classification criteria derived from a set of expert-rated patient scenarios that includes more updated and inclusive definitions for each criterion.
11. Piper, BF. Pathophysiological Phenomena in Nursing: Human Responses to Illness. PA, USA: WB Saunders; 1993. p. 279-302.
12. Krupp LB, Larocca NC, Luft BJ, Halpern JJ. Comparison of neurologic and psychologic findings in patients with Lyme disease and chronic fatigue syndrome. *Neurology.* 1989; 39(Suppl. 39):144. [PubMed: 2535894]

13. Krupp LB, Larocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch. Neurol.* 1989; 46(10): 1121–1123. [PubMed: 2803071]
14. Ramsey-Goldman R, Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. *PMR.* 2010; 2(5):384–392.
15. Da Costa D, Dritsa M, Bernatsky S, et al. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. *J. Rheumatol.* 2006; 33(7): 1282–1288. [PubMed: 16758508]
16. Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. *Lupus.* 1998; 7(2):101–107. [PubMed: 9541094]
17. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. *J. Rheumatol.* 2001; 28(3):525–532. [PubMed: 11296953]
18. Al Dhanhani AM, Gignac MA, Su J, Fortin PR. Work disability in systemic lupus erythematosus. *Arthritis Rheum.* 2009; 61(3):378–385. [PubMed: 19248125]
19. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. *Arthritis Rheum.* 2008; 59(12):1788–1795. [PubMed: 19035422]
20. Neuberger GB, Press AN, Lindsley HB, et al. Effects of exercise on fatigue, aerobic fitness, and disease activity measures in persons with rheumatoid arthritis. *Res. Nursing Health.* 1997; 20(3): 195–204.
21. Ramsey-Goldman R, Schilling EM, Dunlop D, et al. A pilot study on the effects of exercise in patients with systemic lupus erythematosus. *Arthritis Care Res.* 2000; 13(5):262–269. [PubMed: 14635294]
22. Carvalho MR, Sato EI, Tebexreni AS, Heidecher RT, Schenkman S, Neto TL. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2005; 53(6):838–844. [PubMed: 16342102]
23. Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. *Br. J. Rheumatol.* 1989; 28(6):500–505. [PubMed: 2590802]
24. Tench C, Bentley D, Vleck V, Mccurdie I, White P, D'Cruz D. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. *J. Rheumatol.* 2002; 29(3):474–481. [PubMed: 11908559]
25. Campillo B, Fouet P, Bonnet JC, Atlan G. Submaximal oxygen consumption in liver cirrhosis. Evidence of severe functional aerobic impairment. *J. Hepatol.* 1990; 10(2):163–167. [PubMed: 2332586]
26. Keyser RE, Rus V, Cade WT, Kalappa N, Flores RH, Handwerger BS. Evidence for aerobic insufficiency in women with systemic Lupus erythematosus. *Arthritis Rheum.* 2003; 49(1):16–22. [PubMed: 12579589]
27. Zdrengea D, Giurgea N, Predescu D, Timis D, Icusca G. Exercise testing in patients with valvular diseases. *R. J. Inter. Med.* 1994; 32(1):23–28.
28. Bostrom C, Dupre B, Tengvar P, Jansson E, Opava CH, Lundberg IE. Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage. *Lupus.* 2008; 17(2):100–104. [PubMed: 18250132]
29. Volkmann ER, Grossman JM, Sahakian LJ, et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. *Arthritis Care Res.* 2010; 62(2):258–265.
30. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Res. Ther.* 2008; 10(4):213. [PubMed: 18828865]

31. McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. *Arthritis Rheum.* 2009; 60(8):2428–2437. [PubMed: 19644959]
32. Mancuso CA, Perna M, Sargent AB, Salmon JE. Perceptions and measurements of physical activity in patients with systemic lupus erythematosus. *Lupus.* 2011; 20(3):231–242. [PubMed: 21183562] ■ Recent article with a good overview of the barriers to being physically active in SLE.
33. Katz P, Gregorich S, Yazdany J, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. *Arthritis Care Res.* 2011; 63(2):261–268.
34. Katz P, Yazdany J, Julian L, et al. Impact of obesity on functioning among women with systemic lupus erythematosus. *Arthritis Care Res.* 2011; 63(10):1357–1364.
35. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. *Lupus.* 2000; 9(3):170–175. [PubMed: 10805483]
36. Chaiamnuay S, Bertoli AM, Fernandez M, et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. *J. Clin. Rheumatol. Prac. Rep. Rheum. Musculoskeletal Dis.* 2007; 13(3):128–133.
37. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. *Arthritis Rheum.* 2005; 52(11):3651–3659. [PubMed: 16258902]
38. Shah M, Kavanaugh A, Coyle Y, Adams-Huet B, Lipsky PE. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. *J. Rheumatol.* 2002; 29(10):2122–2128. [PubMed: 12375321]
39. Gabriellsson BG, Johansson JM, Lonn M, et al. High expression of complement components in omental adipose tissue in obese men. *Obesity Res.* 2003; 11(6):699–708.
40. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. *J. Clin. Invest.* 1995; 95(5):2409–2415. [PubMed: 7738205]
41. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation.* 2003; 107(3):391–397. [PubMed: 12551861]
42. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. *Circulation.* 2004; 109(16):1955–1959. [PubMed: 15051634]
43. Greenwood KM, Lederman L, Lindner HD. Self-reported sleep in systemic lupus erythematosus. *Clin. Rheumatol.* 2008; 27(9):1147–1151. [PubMed: 18408880]
44. Chandrasekhara PK, Jayachandran NV, Rajasekhar L, Thomas J, Narsimulu G. The prevalence and associations of sleep disturbances in patients with systemic lupus erythematosus. *Modern Rheumatol. Jap. Rheum. Assoc.* 2009; 19(4):407–415.
45. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. *Rheumatology (Oxf.).* 2000; 39(11):1249–1254.
46. Costa DD, Bernatsky S, Dritsa M, et al. Determinants of sleep quality in women with systemic lupus erythematosus. *Arthritis Rheum.* 2005; 53(2):272–278. [PubMed: 15818653]
47. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. *Inflamm. Res. Official J. Eur. Histamine Res. Soc.* 2007; 56(2):51–57.
48. Mckinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. *Arthritis Rheum.* 1995; 38(6):826–834. [PubMed: 7779127]
49. Iaboni A, Ibanez D, Gladman DD, Urowitz MB, Moldofsky H. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. *J. Rheumatol.* 2006; 33(12):2453–2457. [PubMed: 17143980] ■ Good review of sleep patterns in SLE patients.
50. Taylor J, Skan J, Erb N, et al. Lupus patients with fatigue – is there a link with fibromyalgia syndrome? *Rheumatology (Oxf.).* 2000; 39(6):620–623.

51. Valencia-Flores M, Resendiz M, Castano VA, et al. Objective and subjective sleep disturbances in patients with systemic lupus erythematosus. *Arthritis Rheum.* 1999; 42(10):2189–2193. [PubMed: 10524692]
52. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatr. Res.* 1989; 28(2):193–213.
53. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. *Neurology.* 2002; 58(8):1214–1220. [PubMed: 11971089]
54. Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI. Fatigue in patients with systemic lupus erythematosus: the psychosocial aspects. *J. Rheumatol.* 2003; 30(2):283–287. [PubMed: 12563681]
55. Cardenas DD, Kutner NG. The problem of fatigue in dialysis patients. *Nephron.* 1982; 30(4):336–340. [PubMed: 7110464]
56. Krupp LB, Larocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. *J. Rheumatol.* 1990; 17(11):1450–1452. [PubMed: 2273484]
57. Radloff L. The CES-D scale: a self-report depression scale for research in general population. *Appl. Psycho. Meas.* 1977; (1):385–401.
58. Snaith RP. The hospital anxiety and depression scale. *Health Qual. Life Outcomes.* 2003; 1:29. [PubMed: 12914662]
59. Aaronson LS, Teel CS, Cassmeyer V, et al. Defining and measuring fatigue. *Image J. Nursing Scholarship.* 1999; 31(1):45–50.
60. Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. *Arthritis Rheum.* 1998; 41(1):41–47. [PubMed: 9433868]
61. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. *J. Int. Neuropsychol. Soc.* 1997; 3(4):377–386. [PubMed: 9260447]
62. Denburg SD, Carbotte RM, Denburg JA. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. *J. Clin. Exp. Neuropsychol.* 1987; 9(4):323–339. [PubMed: 3597726]
63. Kozora E, Arciniegas DB, Filley CM, et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. *Arthritis Rheum.* 2008; 59(11):1639–1646. [PubMed: 18975359]
64. Beck, AT.; Steer, RA.; Brown, GK. Manual for Beck depression inventory-II. San Antonio, TX: Psychological Corporation; 1996.
65. Broadbent DE, Cooper PF, Fitzgerald P, Parkes KR. The Cognitive failures questionnaire (CFQ) and its correlates. *Br. J. Clin. Psychol.* 1982; 21(Pt 1):1–16. [PubMed: 7126941]
66. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. *J. Clin. Endocrinol. Metab.* 2007; 92(9):3517–3522. [PubMed: 17535985]
67. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. *Am. J. Clin. Nutr.* 2002; 75(4):611–615. [PubMed: 11916748]
68. Cutolo M. Vitamin D and autoimmune rheumatic diseases. *Rheumatology (Oxf.).* 2009; 48(3):210–212.
69. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. *Archives Inter. Med.* 2008; 168(15):1629–1637.
70. Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. *J. Rheumatol.* 2001; 28(11):2535–2539. [PubMed: 11708429]
71. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun. Rev.* 2006; 5(2):114–117. [PubMed: 16431339]
72. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. *Clin. Rheumatol.* 1995; 14(4):397–400. [PubMed: 7586974] ■ Excellent review of the pathophysiology of vitamin D.

73. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxo A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. *Rheumatology (Oxf.)*. 2008; 47(6):920–923.
74. Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. *Arthritis Care Res*. 2010; 62(8):1160–1165.
75. Schur, PH. *General Symptomology* (2nd Edition). PA, USA: Lippincott-Raven; 1996. p. 10
76. Zonana-Nacach A, Roseman JM, Mcgwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5 years of criteria diagnosis. LUMINA study group. *Lupus in minority populations: Nature vs Nurture*. *Lupus*. 2000; 9(2):101–109. [PubMed: 10787006]
77. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. *Arthritis Rheum*. 2007; 57(8):1348–1357. [PubMed: 18050225] ■ Good review of the many fatigue measuring tools and importance of uniformity.
78. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. *J. Rheumatol*. 2005; 32(9):1699–1705. [PubMed: 16142863]
79. Valencia-Flores M, Cardiel MH, Santiago V, et al. Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus. *Lupus*. 2004; 13(1):4–10. [PubMed: 14870911]
80. Tayer WG, Nicassio PM, Weisman MH, Schuman C, Daly J. Disease status predicts fatigue in systemic lupus erythematosus. *J. Rheumatol*. 2001; 28(9):1999–2007. [PubMed: 11550966]
81. Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. *Br. J. Rheumatol*. 1993; 32(7):633–635. [PubMed: 8339141]
82. Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. *Ann. Rheum. Dis*. 1999; 58(6):379–381. [PubMed: 10340963]
83. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. *J. Rheumatol*. 2002; 29(3):482–486. [PubMed: 11908560]
84. Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. *J. Rheumatol*. 1998; 25(5):892–895. [PubMed: 9598886]
85. Burgos PI, Alarcon GS, Mcgwin G Jr, Crews KQ, Reveille JD, Vila LM. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. *Arthritis Rheum*. 2009; 61(9):1179–1186. [PubMed: 19714612]
86. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. *J. Psychosomatic Res*. 1993; 37(2):147–153.
87. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised piper fatigue scale: psychometric evaluation in women with breast cancer. *Oncol. Nurs. Forum*. 1998; 25(4): 677–684. [PubMed: 9599351]
88. Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. *J. Rheumatol*. 1997; 24(8):1608–1614. [PubMed: 9263159]
89. Austin JS, Maisiak RS, Macrina DM, Heck LW. Health outcome improvements in patients with systemic lupus erythematosus using two telephone counseling interventions. *Arthritis Care Res*. 1996; 9(5):391–399. [PubMed: 8997929]
90. Ware, JE.; Kosinski, M.; Keller, SD. *SF-36 Health Survey: Manual and Interpretation Guide*. MA, USA: The Health Institute, New England Medical Center; 1983.
91. Tack BB. Fatigue in rheumatoid arthritis. Conditions, strategies, and consequences. *Arthritis Care Res*. 1990; 3(2):65–70. [PubMed: 2285744]

92. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J. Psychosomatic Res.* 1995; 39(3):315–325.
93. White PD, Grover SA, Kangro HO, Thomas JM, Amess J, Clare AW. The validity and reliability of the fatigue syndrome that follows glandular fever. *Psychol. Med.* 1995; 25(5):917–924. [PubMed: 8588010]
94. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. *J. Psychosomatic Res.* 1993; 37(7):753–762.
95. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. *Nurs. Res.* 1993; 42(2):93–99. [PubMed: 8455994]
96. Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. *Rheumatology (Oxf.)*. 2004; 43(6):758–764.
97. Barcellini W, Rizzardi GP, Borghi MO, et al. *In vitro* Type 1 and Type 2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. *Lupus*. 1996; 5(2):139–145. [PubMed: 8743127]
98. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of Type 1 interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. *Lupus*. 2000; 9(9):664–671. [PubMed: 11199920]
99. Lauwerys BR, Houssiau FA. Cytokines: clues to the pathogenesis of SLE. *Lupus*. 1998; 7(4):211–213. [PubMed: 9643309]
100. Chao CC, Janoff EN, Hu SX, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. *Cytokine*. 1991; 3(4):292–298. [PubMed: 1873478]
101. Krupp LB, Pollina D. Neuroimmune and neuropsychiatric aspects of chronic fatigue syndrome. *Adv. Neuroimmunol.* 1996; 6(2):155–167. [PubMed: 8876771]
102. Rasmussen AK, Nielsen H, Andersen V, et al. Chronic fatigue syndrome – a controlled cross sectional study. *J. Rheumatol.* 1994; 21(8):1527–1531. [PubMed: 7983659]
103. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. *Blood*. 2000; 95(1):56–61. [PubMed: 10607684]
104. Schantz SP, Dimery I, Lippman SM, Clayman GL, Pellegrino C, Morice R. A Phase 2 study of interleukin-2 and interferon- α in head and neck cancer. *Invest. N. Drugs*. 1992; 10(3):217–223.
105. Schiller JH, Storer BE, Witt PL, et al. Biological and clinical effects of intravenous tumor necrosis factor- α administered three times weekly. *Cancer Res.* 1991; 51(6):1651–1658. [PubMed: 1998956]
106. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. *J. Clin. Endocrinol. Metab.* 1998; 83(5):1573–1579. [PubMed: 9589658]
107. Harboe E, Greve OJ, Beyer M, et al. Fatigue is associated with cerebral white matter hyperintensities in patients with systemic lupus erythematosus. *J. Neurol. Neurosurg. Psychiatr.* 2008; 79(2):199–201. [PubMed: 17872980]
108. Omdal R, Sjøholm H, Koldingsnes W, et al. Fatigue in patients with lupus is not associated with disturbances in cerebral blood flow as detected by SPECT. *J. Neurol.* 2005; 252(1):78–83. [PubMed: 15654558]
109. Goodenow C, Reisine ST, Grady KE. Quality of social support and associated social and psychological functioning in women with rheumatoid arthritis. *Health Psychol.* 1990; 9(3):266–284. [PubMed: 2340818]
110. Karlson EW, Liang MH, Eaton H, et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. *Arthritis Rheum.* 2004; 50(6):1832–1841. [PubMed: 15188360]
111. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. *Arthritis Rheum.* 1980; 23(2):146–152. [PubMed: 7362665]
112. Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of a revised and expanded arthritis impact measurement scales health status questionnaire. *Arthritis Rheum.* 1992; 35(1):1–10. [PubMed: 1731806]

113. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med. Care.* 1992; 30(6):473–483. [PubMed: 1593914]
114. Greco CM, Kao AH, Maksimowicz-Mckinnon K, et al. Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study. *Lupus.* 2008; 17(12):1108–1116. [PubMed: 19029279]
115. Yuen H, Holthaus K, Kamen D, Sword D, Breland H. Using Wii Fit to reduce fatigue among African American women with systemic lupus erythematosus: a pilot study. *Lupus.* 2011; 20(12):1293–1299. [PubMed: 21700656]
116. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. *Ann. Rheum. Dis.* 2010; 69(6):1144–1147. [PubMed: 19854713]
117. Derksen RH. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. *Semin. Arthritis Rheum.* 1998; 27(6):335–347. [PubMed: 9662752]
118. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. *J. Rheumatol.* 2005; 32(5):811–819. [PubMed: 15868614]
119. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase 3 trial. *Lancet.* 2011; 377(9767):721–731. [PubMed: 21296403] ■ Large study looking at a new drug for treatment of SLE.
120. Van Vollenhoven R, Zamani O, Wallace DJ. Belimumab, a Blys-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. 2010 (Abstract OP 0068). ■ Large study looking at a new drug for treatment of SLE.

Executive summary

Systemic lupus erythematosus & fatigue

- A total of 53–80% of systemic lupus erythematosus (SLE) patients identify fatigue as one of their primary symptoms. Fatigue results in decreased quality of life, increased risk of work disability and increased healthcare costs.

Factors associated with fatigue

- SLE patients' aerobic capacity is often decreased compared to healthy controls and studies have shown improved health outcomes including decreased fatigue from increasing physical activity.
- Obesity is prevalent in the SLE population, with a BMI above 30 kg/m² associated with worse depression and fatigue.
- A bidirectional relationship exists between fatigue and poor sleep, with SLE cohorts usually experiencing more sleep–wake disturbances and unrestorative sleep.
- Depression has been consistently associated with fatigue and anxiety and mood disorders have been correlated with fatigue in SLE patients compared to healthy controls.
- Suboptimal levels of vitamin D have been reported in the SLE population, with vitamin D deficiency correlating with worse fatigue.
- There is a positive correlation between pain intensity and fatigue in the SLE population.
- No significant associations were found between corticosteroids or NSAID use and fatigue severity.
- Coexisting fibromyalgia, thyroid disease and anemia may also affect fatigue in SLE.
- Conflicting theories exist, with one side showing positive correlation between SLE disease activity and fatigue, and the other arguing for weak or no association.

Measurements of fatigue

- Over 30 scales exist to test fatigue as a research tool.
- Various serum biomarkers for inflammation have been evaluated for their association with fatigue in SLE, including antiphospholipid antibodies, transforming growth factor- β , TNF- α , IL-2, IL-6 and IL-10, with few studies showing positive correlations.
- There have been inconsistent findings correlating the association of levels of fatigue to changes of brain imaging using different modalities including MRI and single-photon emission computed tomography.

Therapeutic trials

- Different therapies have been studied to improve fatigue in SLE: psychoeducational intervention to increase wellbeing, computer gaming modules to increase physical activity, acupuncture to decrease fatigue and

pain and medication trials with dehydroepiandrosterone, belimumab, and vitamin D3, with some showing positive results.